Labidi-Galy SI, de La Motte Rouge T, Derbel O, et al. - In this multicenter (eight hospitals) European retrospective study of women with relapsing epithelial ovarian cancer (EOC; n = 115) having germline or somatic mutations of BRCA1/BRCA2 genes and treated with olaparib as maintenance therapy following platinum-based chemotherapy, researchers examined clinical factors related to prolonged progression-free survival (PFS) and overall survival (OS) in women with relapsing EOC with BRCA mutations. There were 90 BRCA1 carriers, 24 BRCA2 carriers, and one with germline mutation of BRCA1 and BRCA2. Six had somatic mutations (all BRCA1) and 109 had germline mutations. In relapsing BRCA1/BRCA2 mutated ovarian cancer individuals who received olaparib as maintenance therapy, platinum-free interval ≥ 12 months, complete response and normalized CA-125 levels following ultimate platinum-based chemotherapy were discovered to be correlated with prolonged PFS and OS.